Irinotecan and colorectal cancer: the role of p53, VEGF-C and alpha-B-crystallin expression.
Weekes
Jessica
J
Ho
Yik-Hong
YH
Sebesan
Sabe
S
Ong
Kate
K
Lam
Alfred King-Yin
AK
D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000191:economics / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry / Q000191:economics; D000077146:Irinotecan; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*; D042582:Vascular Endothelial Growth Factor C / Q000378:metabolism*; D038203:alpha-Crystallin B Chain / Q000378:metabolism*
D000972:Antineoplastic Agents, Phytogenic; D016159:Tumor Suppressor Protein p53; D042582:Vascular Endothelial Growth Factor C; D038203:alpha-Crystallin B Chain; D000077146:Irinotecan; D002166:Camptothecin